What is Ygeia3?
Ygeia3 operates at the intersection of biotechnology and corporate performance, serving as a premier provider of advanced scientific wellness testing. The company distinguishes itself by delivering actionable laboratory insights to corporations, collegiate athletic programs, and professional sports organizations. By integrating rigorous scientific methodology into the daily operations of its clients, Ygeia3 enables a proactive approach to health management, moving beyond traditional wellness programs toward precision-based performance optimization. Its market position is defined by its ability to translate complex biological data into scalable, enterprise-ready solutions that enhance human capital efficiency.
How much funding has Ygeia3 raised?
Ygeia3 has raised a total of $1M across 1 funding round:
Debt
$1M
Debt (2020): $1M with participation from PPP
Key Investors in Ygeia3
PPP
Public-Private Partnership
What's next for Ygeia3?
With the successful closure of this major strategic investment, Ygeia3 is well-positioned to expand its laboratory footprint and enhance its diagnostic capabilities. The strategic roadmap likely involves scaling its proprietary testing platform to accommodate a broader range of enterprise clients while investing in R&D to refine its predictive health analytics. As the demand for evidence-based wellness solutions continues to rise within the corporate sector, Ygeia3 is poised to leverage its current momentum to capture additional market share. Future growth will likely focus on deepening its integration with existing corporate health management systems, ensuring that its scientific insights remain a cornerstone of organizational performance strategies.
See full Ygeia3 company page
